Jade Biosciences filings document a Nasdaq-listed clinical-stage biotechnology issuer developing antibody therapies for autoimmune diseases. Form 8-K reports furnish operating and financial results and attach corporate updates covering JADE101, JADE201, JADE301, research progress, and liquidity-related disclosures.
The company's proxy and material-event filings cover annual meeting matters, board and officer changes, compensatory arrangements, employment inducement stock plans, material agreements, private placement securities, common stock and pre-funded warrant terms, and other capital-structure disclosures. The filings also identify Jade as an emerging growth company with common stock registered under the Exchange Act.
Jade Biosciences, Inc. (JBIO) filed a prospectus supplement to update its Form S-1 with information from its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The company reported a net loss of $40.4 million for the quarter and used $24.1 million of cash in operations. Cash and cash equivalents were $55.1 million and investments were $256.2 million, totaling $311.3 million as of March 31, 2026. Shares outstanding were 49,359,875 as of May 1, 2026. The prospectus supplement also discloses an Open Market Sales Agreement entered May 7, 2026, under which the company may sell up to $200.0 million of common stock in at‑the‑market offerings (the company has not sold any shares under that agreement to date).
Jade Biosciences, Inc. files a prospectus supplement to its Form S-1 to update the offering document with information from its Form 10-Q for the quarter ended March 31, 2026. The supplement relates to Common Stock offered by selling stockholders and references a recent May 7, 2026 Form 10-Q.
The 10-Q discloses cash and cash equivalents of $55.1 million, investments of $256.2 million (totaling $311.3 million), a net loss of $40.4 million for the three months ended March 31, 2026, and 49,359,875 shares outstanding as of May 1, 2026. The supplement updates risk and operational disclosures and attaches the quarterly financial statements.
Jade Biosciences, Inc. reported a larger quarterly loss as it ramps up autoimmune drug development. For the three months ended March 31, 2026, the company recorded a net loss of $40.4 million, compared with $38.2 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $36.1 million, and general and administrative costs increased to $7.4 million as Jade expanded its organization and pipeline. Operating cash outflow was $24.1 million in the quarter.
The balance sheet remains strong, with $55.1 million in cash and cash equivalents and $256.2 million in investments, totaling $311.3 million of liquid resources as of March 31, 2026. Management believes this will fund operating and capital needs for at least twelve months from the financial statement issuance date.
Jade is advancing three biologic candidates: JADE101 for IgA nephropathy, JADE201 for rheumatoid arthritis and other autoimmune diseases, and JADE301 targeting an undisclosed pathway, with multiple Phase 1 and Phase 2 trials expected to start or deliver interim data between 2026 and 2027.
Jade Biosciences, Inc. reported first quarter 2026 financial results and highlighted progress across its autoimmune disease pipeline. The company is advancing JADE101, a selective anti-APRIL antibody for IgA nephropathy, with initial biomarker-rich Phase 1 data expected and a Phase 2 trial planned.
Additional programs include JADE201, an afucosylated anti-BAFF-R antibody, and JADE301, an undisclosed antibody candidate, both targeting autoimmune indications. For the quarter ended March 31, 2026, Jade recorded a net loss of $40,368 thousand on operating expenses of $43,445 thousand, driven mainly by $36,053 thousand in research and development spending.
Cash, cash equivalents and investments totaled $311,295 thousand as of March 31, 2026, supporting ongoing clinical development. The company’s forward-looking statements note the potential for its cash runway to extend into the first half of 2028, while emphasizing typical clinical, regulatory and funding risks.
Jade Biosciences, Inc. is asking stockholders at its virtual June 9, 2026 annual meeting to elect two Class II directors, ratify PricewaterhouseCoopers LLP as auditor for 2026, and approve an amendment to its articles of incorporation adding a jury trial waiver for certain internal corporate actions under Nevada law.
The company is a clinical-stage biopharmaceutical business focused on biologic therapies for autoimmune diseases, with lead antibody programs JADE101, JADE201 and JADE301. Jade has a classified six‑member board, approximately 83% independent, with fully independent audit, compensation, and nominating and corporate governance committees, and policies including a code of conduct, clawback, and prohibitions on hedging and pledging.
PWC billed audit fees of $1.52 million in 2025 after replacing KPMG, which was dismissed without reported disagreements. As of March 15, 2026, 49,316,287 shares were outstanding, with several institutional holders each owning more than 5%. The proxy outlines detailed executive and director compensation, including option-heavy packages and change‑in‑control severance protections.
BlackRock, Inc. amended a Schedule 13G to report beneficial ownership of 2,295,825 shares of JADE BIOSCIENCES INC common stock, representing 4.7%.
The filing states sole voting power of 2,257,003 shares and sole dispositive power of 2,295,825 shares. The amendment is signed by Spencer Fleming on 04/27/2026.
Jade Biosciences, Inc. reported that its Board of Directors appointed Andrew King, BVMS, Ph.D. as the company’s President, Research & Development, effective April 18, 2026. Dr. King previously served as Chief Scientific Officer and Head of Research & Development, and his compensation was unchanged with this new role.
Jade Biosciences, Inc. is seeking stockholder action at its virtual 2026 Annual Meeting on June 9, 2026, including election of two Class II directors, ratification of PricewaterhouseCoopers LLP as auditor and approval of an amendment to waive jury trials for certain "internal actions."
The proxy summarizes the April 28, 2025 business combination that created the current Jade structure; immediately after the Merger, Pre-Merger Jade securityholders owned approximately 98.6% of the company on a fully diluted basis and Aerovate securityholders owned approximately 1.4%. Shares outstanding were 49,316,287 as of March 15, 2026, and the record date for voting is April 17, 2026.
Jade Biosciences, Inc. reported that its Board of Directors approved the 2026 Employment Inducement Stock Incentive Plan. The plan is intended for new employees as an inducement to join the company, in line with Nasdaq Listing Rule 5635(c)(4).
The Board initially reserved 1,750,000 shares of common stock for awards under the plan. It is substantially similar to the company’s 2025 Stock Incentive Plan, but it does not permit incentive stock options and may only grant awards to eligible recipients under applicable Nasdaq rules.